Related Experiment Video
Updated: Jul 17, 2025
11:02
Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
21.3K
Prediction for recurrent non-muscle invasive bladder cancer
Keqiang Li1,2, Aravind Raveendran1, Guoqing Xie1,2
1Laboratory Urology, Department of Urology, The First Affiliated Hospital of Zhengzhou University, Henan, China.
Cancer Biomarkers : Section a of Disease Markers
|September 4, 2023
Summary
Predicting recurrence risk for non-muscle invasive bladder cancer (NMIBC) is crucial. This review covers liquid biopsy, tissue biopsy, and risk tables to aid precision medicine and public health efforts.
Area of Science:
- Urology
- Oncology
- Biomarkers
Background:
- Non-muscle invasive bladder cancer (NMIBC) frequently recurs, posing significant patient and healthcare burdens.
- Accurate recurrence risk prediction is vital for effective NMIBC management and treatment stratification.
Purpose of the Study:
- To provide a comprehensive overview of current recurrence risk prediction tools for NMIBC.
- To analyze the advantages and disadvantages of various prediction methodologies.
Main Methods:
- Review of primary recurrence risk prediction tools: liquid biopsy, tissue biopsy, and risk prediction tables.
- Detailed description and illustrative examples of each tool.
- Comparative analysis of tool efficacy, accessibility, and limitations.
Main Results:
- Liquid biopsy offers non-invasive monitoring potential.
- Tissue biopsy provides cellular-level diagnostic information.
- Risk prediction tables offer accessible, data-driven prognostic insights.
Conclusions:
- Emerging technologies are enhancing NMIBC recurrence prediction capabilities.
- Understanding the strengths and weaknesses of each tool is key for clinical application.
- These tools support the advancement of precision medicine and public health strategies in bladder cancer care.
